Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on blood transfusion safety and pathogen-protected blood components. These filings offer detailed information on the company’s financial performance, business risks, and corporate governance.
Investors can review current reports on Form 8-K, which Cerus uses to furnish press releases announcing quarterly financial results, such as second and third quarter 2025 earnings. These 8-K filings summarize product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, government contract revenue related to INTERCEPT RBC and other development programs, and updates to annual product revenue guidance.
Cerus’ periodic reports on Form 10-K and Form 10-Q, referenced in company press releases, include sections such as “Risk Factors” that discuss uncertainties related to commercialization of the INTERCEPT Blood System, regulatory approvals for the INTERCEPT RBC system, development of technologies like INT200 and lyophilized IFC, supply chain considerations, and macroeconomic and geopolitical risks.
Through this page, users can also monitor disclosures about board and leadership changes, such as those reported in Form 8-K filings covering director retirements and appointments of new board leadership roles. These documents provide context on the company’s governance structure.
Stock Titan enhances these filings with AI-powered tools that summarize lengthy documents, highlight key items such as revenue trends, development program updates, and risk factor changes, and help readers navigate complex regulatory language. Users can quickly locate information on topics like product revenue composition, government contract funding, and the status of clinical and regulatory programs related to Cerus’ INTERCEPT technologies.
Cerus Corporation (CERS) filed a Form 8-K to announce a governance change effective June 16, 2025. Long-standing board chair Daniel N. Swisher, Jr. retired from the board and its committees with no reported disagreements over company matters. To maintain continuity, the board moved quickly on June 20 to promote CEO William M. Greenman to chair while appointing Frank Witney, Ph.D. as lead independent director. Both directors will serve in their existing board classes, expiring at the 2026 and 2027 annual meetings, respectively. No other operational or financial data were disclosed in the filing.
The change consolidates the CEO and chair roles, offset by the creation of a lead independent director position intended to preserve board oversight. Investors should view the update as a routine succession matter with limited immediate financial impact but modest corporate-governance implications.